Medicine: as prescribed
by your DNA.Using DNA to guide treatment is especially important for the really dangerous diseases where trial and error remains the standard of care.
We are changing the way the largest and deadliest diseases are treated.
Medicine: as prescribed
by your DNA.We are changing the way the largest and deadliest diseases are treated.
What if you were only prescribed the right drugs?
The ones that make you better faster.
More lives saved. Less healthcare spending.
We’re different in many ways, but mostly because before selling anything we generate clinical and economic evidence on our patented tests. Geneticure tests go well beyond drug metabolism. Think complex assays and treatment algorithms for complex diseases specific to each disease.
This commitment to evidence and integrative physiology produces actionable tests that will really improve outcomes and will make make this longstanding promise of personalized medicine a reality. Especially for the largest, deadliest and costliest diseases.
Our Team
Scientific Team
Eric Snyder, PhD
Chief Operating Officer
Dr. Snyder completed his PhD at the University of Minnesota and performed his research training at Mayo Clinic as a pre-doctoral fellow and post-doctoral fellow in Cardiovascular Diseases and a second pre-doctoral fellowship in Nephrology and Hypertension. He was an assistant professor in the College of Pharmacy at the University of Arizona and then moved on to the University of Minnesota before co-founding Geneticure.
Ryan Sprissler, PhD
Chief Scientific Officer
Dr. Sprissler is a founding member of the Center for Applied Genetics and Genomic Medicine and Lead Scientist managing the University of Arizona Genetics Core facility specializing in cutting edge genomic technology. An industry pioneer, he has leveraged several partnerships fueling the high growth industry of genomic testing. With 15 years of experience in genetic assay design/testing he is a current member of the Association for Bioresource Facilities (ABRF), the Association for Laboratory Automation (ALA) & the American Association for the Advancement of Science (AAAS)
Thomas Olson, PhD
Chief Clinical Officer
Dr. Olson is an Associate Professor of Medicine and Science and Consultant in the Department of Cardiovascular Medicine at Mayo Clinic where he sees patients in the Division of Preventive Cardiology. He is the Director of the Clinical Integrative Physiology Research Laboratory which is funded by the National Institutes of Health, American Heart Association, and Industry.
Timothy Curry, MD, PhD
Medical Director
Dr. Curry has lead large clinical pharmacogenomic implementation projects and is a leader in pharmacogenomic education. He is the Director of the Education Program of the Mayo Clinic Center for Individualized Medicine as well as the Vice Chair of Practice for the Department of Anesthesiology and Perioperative Medicine, also at Mayo Clinic. He is also an integrative physiologist with special expertise in cardiopulmonary and neural physiology.
Monica Akre, PhD
Director of Laboratory Development
Dr. Akre spent 6 years in the Cytogenetics department at Mayo Clinic before moving to the University of Minnesota for graduate studies where she worked on identification of pharmacogenomic biomarkers. Her focus is to ensure expansion of personalized medicine to promising ventures. Current focus is prediction of drug response in hematologic malignancies.Business and Informatics Team
Scott Snyder
CEO
Scott spent 15 years in CPG consumer insights and analytics, primarily for Target Corporation in Minneapolis. Most recently to Geneticure he lead a strategic advisory group for over $10 Billion of consumer categories including OTC Pharmacy for Target Corporation. His other longtime passion has been in developmental stage biotechnology, which led to Geneticure with his co-founders Eric, Ryan and Tom.
David Herbert, MBA
EVP of Strategy
David spent over 20 years in leadership roles at Mayo Clinic, including Chief Administrative Officer of Mayo Medical Laboratories; Chair of Mayo Clinic Global Business Solutions; and Director of Technology Commercialization at Mayo Medical Ventures. David is an emeritus member of the Mayo Clinic staff and is a board member and treasurer of the national Myotonic Dystrophy Foundation.
Don Wright
Sr. Advisor
Don Wright spent the past decade growing Assurex Health from technology invented at Mayo Clinic and Cincinnati Children’s Hospital Medical Center to a company of almost 500 employees serving over 500,000 people with mental health conditions. Assurex Health was acquired in 2016 by Myriad Genetics allowing Don to use his more than 25 years of experience in the informatics, product development, operations and life sciences fields, to assisting others turn their ideas into hyper-growth companies.
Ben Bowman, MBA
SVP of Business Development & Strategy
Ben has decades of experience leading companies through all stages of growth and renewal. Heis especially respected for his ability to apply lean startup methodologies to fast growing
companies. He currently serves as an industry advisor to the University of Minnesota’s
technology transfer office. In his previous venture, General Blood, Ben created a national
market for donated human blood through the use of a dynamic and novel online exchange.
Joshua White
Director of Information Technology
Josh is an Information technology specialist focused on big data, visualization, artificial intelligence, and machine learning. Formerly IT Manager and process automation for BIO5 and Arizona Research Labs at University of Arizona. Consultant since 2007 managing and developing eCommerce, federal data analysis, and health technology products for with UnderArmour, Bloomberg LP, SCI Solutions, Johnston Controls, Siemens, and multiple startups.
Carl Jepsen, MBA
Director of Operations
Carl has 16 years of banking, finance and commercial real estate experience. Before joining Geneticure, he held several positions at Wells Fargo Bank N.A., most recently as a Business Relationship Manager. In that position, he consulted with clients and prospective clients regarding process management, growth, transition, and business strategies.
Matthew Sprissler, JD
Internal Counsel
Matthew has a broad spectrum of experience in business related legal affairs, including: funding agreements, employment law, patent and trademark law, contract law, and Federal, State, and Local Agency regulation. He has also managed many litigation matters to include patent infringement, trademark infringement, and contract and employment disputes.Evidence
Completed and Ongoing Clinical Trials:
Relationship Between Genes Important in Blood Pressure Regulation and Blood Pressure Therapy in
Hypertension. Clinicaltrials.gov identifier: NCT02524873. Completed.
Investigating the Use of Genetics to Guide Pharmacologic Therapy for Hypertension. Clinicaltrials.gov
identifier: NCT02988245. Ongoing.
Association Between a Genetic Algorithm to Predict Hypertension Therapy and Response to Treatment.
Clinicaltrials.gov identifier: NCT03292900.
Presentations at National and International Meetings:
Multi-gene Pharmacogenetics and Blood Pressure Control in Patients with Hypertension. MW Johnson,
R Sprissler, TP Olson, GW Beenken, and EM Snyder. Presented at the American Society for Health-
System Pharmacies, 2016. The FASEB Journal, 30(1) 942.1.
Time to Blood Pressure Control According to Drug Class in Patients with Hypertension. MW Johnson, R
Sprissler, TP Olson, GW Beenken, and EM Snyder. Presented at the American Society for Health-System
Pharmacies, 2016. The FASEB Journal, 30(1) 942.12.
The Integrative Nature of Pharmacogenetics of Hypertension: Moving Beyond Drug Metabolizing
Enzymes. EM Snyder, R Sprissler, and TP Olson. Presented at the Mayo Clinic Center for Individualized
Medicine Annual Meeting, October, 2016.
Genes Predicting the Response to Beta-Blockade may Also Influence the Blood Pressure Response to
Diuretic Therapy. EM Snyder, R Sprissler, and TP Olson. Presented at the Mayo Clinic Center for
Individualized Medicine Annual Meeting, October, 2017.
Influence of genes important in renal sodium handling and the blood pressure response to a diuretic in
hypertension. J Ross, D Walla, EM Snyder, R Sprissler, TP Olson, and P Phelps. Presented at the American
Society for Health-System Pharmacists Annual Meeting. 2017.
Influence of genes involved in the renin-angiotensin- aldosterone system and the blood pressure
response to angiotensin receptor blockade in hypertension. D Walla, J Ross, EM Snyder, R Sprissler, TP
Olson, and P Phelps. Presented at the American Society for Health-System Pharmacists Annual Meeting.
2017.
Peer-Reviewed Manuscript:
Association of a Multi-Gene Panel with Blood Pressure Medication Success in Patients with
Hypertension. Eric M. Snyder, Ryan Sprissler, Micah Johnson, Greg D. Beenken, Timothy Curry, Nicholas
Cassuto, and Thomas P. Olson. Under Review at: Clinical Medicine Insights, Cardiology.
Get in Touch
For our latest updates and news: